main content start
Showing Results for: “Contact ”
New Hampshire
Safe at School: New Hampshire
Leading the Fight for Insulin Affordability
Stay up-to-date on the latest developments in the fight for affordable insulin. Discover how you can take advantage of new cost-sharing limits and find resources to lower your insulin costs.
Protect Your Eyes
Discover practical tips to protect your eye health with diabetes, including regular eye exams, UV protection, and everyday habits that can help prevent vision loss and complications.
Attendance
Protect your child's rights to receive accommodations for school attendance policies. Learn how to advocate for fair treatment and equal opportunities for students with diabetes.
Emergency Lockdown Preparation
For students with diabetes, stay prepared for emergency lockdown situations at school. Learn how to ensure your child's safety and access to supplies and food in case of a lockdown
Teplizumab Delays Clinical Diagnosis of Type 1 Diabetes, an Average of Two Years, According to Study Presented at ADA’s Scientific Sessions
The Teplizumab Prevention Trial has given validity to the concept that immune therapy can delay the diagnosis of type 1 diabetes (T1D), according to findings presented at a symposium entitled “New Therapeutic Approaches and Insights for Type 1 Diabetes” today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Family members of someone with T1D have a 15 times greater risk of developing T1D than individuals from the general population. Testing can determine the presence of autoantibodies, indicating risk for T1D, and the
New Recommendations for Time-in-Range Targets During Continuous Glucose Monitoring Presented Today at the ADA’s Scientific Sessions
Evidence-based guidelines for Continuous Glucose Monitoring (CGM) have been determined by an international panel of diabetes experts striving for consistent parameters for CGM blood glucose level goals in both research and clinical settings, according to a presentation today of the abstract titled “CGM-Based Clinical Targets: Recommendations from the International Consensus on Time-in-Range (TIR)” at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at Moscone Convention Center in San Francisco. The group’s recommendations are also published online today as a manuscript
Give Today and Change lives!
With your support, the American Diabetes Association® can continue our lifesaving work to make breakthroughs in research and provide people with the resources they need to fight diabetes.